Nimesulide-loaded nanoparticles for the potential coadjuvant treatment of prostate cancer.

Nimesulide (NS)-loaded nanoparticles (NPNS) were prepared from polylactide-co-glycolide (PLGA) and eventually coated with chitosan (NPNSCS). Nanoparticles (NP) were spherical with sizes 379 ± 59 nm for NPNS and 393 ± 66 nm for NPNSCS and zeta potentials of -15 ± 3 mV for NPNS to 10 ± 4 mV for NPNSCS, suggesting an efficient coating. Drug encapsulation rate was high (88 ± 5% and 83 ± 7% of added drug) for NPNS and NPNSCS, respectively. After NP washing and re-suspension, 98 ± 2% and 99 ± 1% of the drug initially entrapped remained associated to NP. NS was dispersed in amorphous state within the polymeric matrix. Two-fold dilution of NP with pH 7.4 PBS provoked no drug release. However, 30-40% NS was released after a 1/10 dilution. NPNSCS and NPNS diluted 1/100 reduced the encapsulated drug to around 30% and 70%, respectively. In contrast, 100% NS was released from NP under sink conditions in less than 2h. The permeability of free-NS (1-1.5 × 10(-5)cm/s) was compared with NPNS (NPNS = 6.4-8.1 × 10(-6)cm/s and NPNSCS = 5.5-7.0 × 10(-6)cm/s) using the PAMPA assay. The cytotoxicity of free-NS and NS in NP on model prostate cancer cells PC-3 and DU-145 showed the highest cytotoxic effect with NPNSCS on PC-3 cells (IC50 = 89 μM).

[1]  Justin M. Balko,et al.  Intratumoral Delivery of Paclitaxel in Solid Tumor from Biodegradable Hyaluronan Nanoparticle Formulations , 2009, AAPS PharmSciTech.

[2]  R. Raffin,et al.  Natural lipid nanoparticles containing nimesulide: synthesis, characterization and in vivo antiedematogenic and antinociceptive activities. , 2012, Journal of biomedical nanotechnology.

[3]  S. Guterres,et al.  Human skin penetration and distribution of nimesulide from hydrophilic gels containing nanocarriers. , 2007, International journal of pharmaceutics.

[4]  Xiaoling Li,et al.  Effect of Drug Lipophilicity and Ionization on Permeability Across the Buccal Mucosa: A Technical Note , 2008, AAPS PharmSciTech.

[5]  Ick Chan Kwon,et al.  Targeted delivery of low molecular drugs using chitosan and its derivatives. , 2010, Advanced drug delivery reviews.

[6]  B. Sarma,et al.  Phase transformation in conformational polymorphs of nimesulide. , 2011, Journal of pharmaceutical sciences.

[7]  M. Bondì,et al.  Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies , 2009 .

[8]  S. Uzzau,et al.  Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies , 2011, Nanoscale research letters.

[9]  A. Bernareggi,et al.  Pharmacokinetics of nimesulide , 2005 .

[10]  J. Masferrer,et al.  COX‐2 is expressed in human pulmonary, colonic, and mammary tumors , 2000, Cancer.

[11]  Naresh Kumar,et al.  OCULAR DELIVERY OF ACYCLOVIR VIA MUCOADHESIVE NANOPARTICLES , 2012 .

[12]  C. Hascicek,et al.  Formulation and Optimization of Nonionic Surfactants Emulsified Nimesulide-Loaded PLGA-Based Nanoparticles by Design of Experiments , 2013, AAPS PharmSciTech.

[13]  Ande Bao,et al.  Effect of intratumoral administration on biodistribution of 64Cu-labeled nanoshells , 2012, International journal of nanomedicine.

[14]  C. Cho,et al.  Practical preparation procedures for docetaxel-loaded nanoparticles using polylactic acid-co-glycolic acid , 2011, International journal of nanomedicine.

[15]  J. Nagy,et al.  Synthesis of Nimesulide Nanoparticles in the Microemulsion Epikuron/Isopropyl Myristate/Water/n-Butanol (or Isopropanol) , 2001 .

[16]  Yunqian Pan,et al.  The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  Cynthia K. Brown,et al.  FIP/AAPS Guidelines for Dissolution/In Vitro Release Testing of Novel/Special Dosage Forms* , 2003 .

[18]  Andrew Dannenberg,et al.  COX-2 in cancer--a player that's defining the rules. , 2002, Journal of the National Cancer Institute.

[19]  R. Jain,et al.  Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.

[20]  K. Yadav,et al.  Formulation Development and Characterization of Solid Lipid Nanoparticles Containing Nimesulide , 2009 .

[21]  J. Richie,et al.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D. Voinovich,et al.  In vitro nimesulide absorption from different formulations. , 2004, Journal of pharmaceutical sciences.

[23]  Claus-Michael Lehr,et al.  Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. , 2007, Nanomedicine : nanotechnology, biology, and medicine.

[24]  R. Hayeshi,et al.  Permeation of PLGA nanoparticles across different in vitro models. , 2012, Current drug delivery.

[25]  K. Rainsford.  The discovery, development and novel actions of nimesulide , 2005 .

[26]  P. Amareshwar,et al.  Preparation and characterization of nimesulide loaded cellulose acetate hydrogen phthalate nanoparticles by salting out technique , 2013 .

[27]  Cynthia K. Brown,et al.  FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms , 2008, AAPS PharmSciTech.

[28]  Cheol-Sang Kim,et al.  The intracellular uptake ability of chitosan-coated Poly (D,L-lactideco-glycolide) nanoparticles , 2008, Archives of pharmacal research.

[29]  P. Amareshwar,et al.  Chitosan nanoparticles as a drug delivery system , 2010 .

[30]  Heike Bunjes,et al.  Lipid nanoparticles for the delivery of poorly water‐soluble drugs , 2010, The Journal of pharmacy and pharmacology.

[31]  J. Vishwanatha,et al.  Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. , 2009, Anticancer research.

[32]  V. Sanna,et al.  Nanoparticle therapeutics for prostate cancer treatment. , 2012, Maturitas.

[33]  Robert Langer,et al.  Nanoparticle technologies for cancer therapy. , 2010, Handbook of experimental pharmacology.

[34]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[35]  Lingxue Kong,et al.  Chitosan-Modified PLGA Nanoparticles with Versatile Surface for Improved Drug Delivery , 2013, AAPS PharmSciTech.

[36]  Apurva Kulkarni.  Modification of gold markers with Doxorubicin as Radiosensitizer encapsulated in sustained release PLGA nanoparticles to enhance Image Guided Radiotherapy (IGRT) , 2011 .

[37]  M. Singh,et al.  The influence of various methods of cold storage of skin on the permeation of melatonin and nimesulide. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[38]  T. Nagaraj,et al.  Preparation and Evaluation of Nimesulide-loaded Ethylcellulose and Methylcellulose Nanoparticles and Microparticles for Oral Delivery , 2009, Journal of biomaterials applications.

[39]  S. Parveen,et al.  Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. , 2011, European journal of pharmacology.

[40]  R. Lai,et al.  Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy. , 2010, Molecular pharmaceutics.

[41]  A. Pohlmann,et al.  Semi-solid topical formulations containing nimesulide-loaded nanocapsules showed in-vivo anti-inflammatory activity in chronic arthritis and fibrovascular tissue models , 2012, Inflammation Research.

[42]  Y. Tabata,et al.  In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable gelatin hydrogel. , 2003, Journal of controlled release : official journal of the Controlled Release Society.